Thursday, November 17, 2016 8:03:04 AM
"We believe Biofungicide CR-10 may be a solution to the marijuana mold and fungus issue and need more extensive testing to determine viability”, said CEO Jean Ekobo, and went on to say “With the legalization of marijuana in more states and if the tests are successful, we believe that Biofungicide CR-10 could become a critical protection for the marijuana industry.”
Senior chemical engineer Bjoern Fritzsche, from Rose City Laboratories in Portland, Oregon (www.rosecitylabs.com), said on its report that on average, 15-20 percent of all cannabis tested in Oregon is being rejected due to high levels of toxic molds. In addition, senior micro biologist Steven McNalley, of Analytical 360, in Seattle (www.analytical360.com) reported similar results for the State of Washington. Mr. McNalley added that this number is much higher than the test results reveal as the 20 percent rejection rate only accounts for the final product that is submitted for testing. According to Arcview Market Research (http://www.arcviewmarketresearch.com), “by 2020 legal cannabis sales in the United States are projected to hit $21.8 billion.”
About Biofungicide CR-10
CR-10 is a proven, biodegradable, non-toxic solution that kills bacteria, fungi and spores rapidly, safely and effectively. It is a new generation of biofungicide with a unique mode of action. BioNovelus management believes that CR-10 has a broad range of uses in agricultural applications which now may include marijuana. If you are a marijuana company or know of one that would like to test CR-10 please contact us.
About BioNovelus Inc.
Everything I post is my opinion and only my opinion - if you read enough of my posts, you'll probably realize it's not an opinion that you'd like to take as advice or a recommendation. You've been warned.
Recent CTM News
- Castellum, Inc. Announces New Strategic Alliance • GlobeNewswire Inc. • 04/18/2024 10:45:00 AM
- Castellum, Inc. Announces 2023 Financial Results • GlobeNewswire Inc. • 03/21/2024 10:45:00 AM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 02/27/2024 10:22:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 09:33:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:02:34 PM
- Castellum, Inc. Announces Closing of $4 Million Revolver with Live Oak Bank • GlobeNewswire Inc. • 02/23/2024 11:45:00 AM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 02/16/2024 09:43:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 11:31:23 AM
- Castellum Announces Closing of $2.7 Million Registered Direct Offering • GlobeNewswire Inc. • 01/29/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 11:32:36 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/29/2024 11:31:16 AM
- Castellum Announces Pricing of $2.7 Million Registered Direct Offering • GlobeNewswire Inc. • 01/25/2024 01:55:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/13/2023 05:15:24 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/01/2023 09:02:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 09:08:32 PM
- Castellum, Inc. Announces Execution of Debt Term Sheet • GlobeNewswire Inc. • 11/27/2023 11:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:06:08 PM
- Castellum, Inc. Announces Third Quarter Financial Results • GlobeNewswire Inc. • 11/14/2023 11:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 08:05:41 PM
- Castellum, Inc. Announces Bob Eisiminger, as Senior Advisor • GlobeNewswire Inc. • 10/31/2023 10:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/20/2023 08:04:03 PM
- Castellum, Inc. Announces 2024 Budget Targets and Strategic Initiatives • GlobeNewswire Inc. • 10/20/2023 10:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2023 08:15:24 PM
- Castellum Announces the Award of a $3 million Contract to its Specialty Systems, Inc. Subsidiary • GlobeNewswire Inc. • 08/29/2023 10:45:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM